# A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

> **NCT00712322** · PHASE2 · TERMINATED · sponsor: **Warner Chilcott** · enrollment: 35 (actual)

## Conditions studied

- Neurogenic Detrusor Overactivity

## Interventions

- **DRUG:** Darifenacin

## Key facts

- **NCT ID:** NCT00712322
- **Lead sponsor:** Warner Chilcott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10-07
- **Primary completion:** 2013-05-23
- **Final completion:** 2013-05-23
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Due to extremely difficult enrollment.
- **Last updated:** 2022-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00712322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00712322, "A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00712322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*